BLOG

precision_oncology

Theseus Pharmaceuticals Addressing KIT, EGFR Resistance With Pan-Variant Inhibitors

Theseus Pharmaceuticals is developing targeted pan-variant treatment programs that it envisions can help patients who have relapsed on multiple lines of therapy and be used as pre-emptive strategies in earlier lines to stave off resistance.